AROA BIOSURGERY ORD
Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26
Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.
Aroa Biosurgery maintains cash flow momentum as Myriad Matrix product sales hit record high
Soft tissue regeneration specialist Aroa Biosurgery (ASX: ARX) has posted its second consecutive quarter of positive cash flow, in a period that also saw the company reach a key milestone with over 100 published peer reviews now validating its ECM platform in pre-clinical and clinical studies. Cash flow for the three months to end-March totalled […]
Aroa Biosurgery gains US and EU clearance for complex wound healing products
Newly-listed soft tissue regeneration company Aroa Biosurgery (ASX: ARX) has announced that its Symphony and Myriad complex wound healing products have gained clearance from international regulators. Symphony has received approval from the US Food and Drug Administration, while Myriad received European regulatory approval via CE Mark certification. Both approvals were confirmed by Aroa this morning […]
Aroa Biosurgery plans ASX listing to corner complex wound healing market
Auckland-based soft tissue regeneration company Aroa Biosurgery is set to list on the Australian Stock Exchange next month following an initial public offering aimed at raising $45 million from investors. The offer will comprise $30 million in primary capital through the issue of 40 million new shares at $0.75 each, while the remaining $15 million […]